EP2624897A1 - Inhalateur comprenant une capsule - Google Patents

Inhalateur comprenant une capsule

Info

Publication number
EP2624897A1
EP2624897A1 EP11787953.6A EP11787953A EP2624897A1 EP 2624897 A1 EP2624897 A1 EP 2624897A1 EP 11787953 A EP11787953 A EP 11787953A EP 2624897 A1 EP2624897 A1 EP 2624897A1
Authority
EP
European Patent Office
Prior art keywords
inhaler
capsule
intake duct
air intake
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11787953.6A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2624897A1 publication Critical patent/EP2624897A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A61M15/0026—Hinged caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer

Definitions

  • the present invention relates to an inhaler suitable for administration of drugs in dry powder form used in the prophylaxis and the treatment of respiratory tract diseases by the inhalation route.
  • inhalers for delivering medicaments utilized in the treatment and prophylaxis of respiratory diseases.
  • Inhalation treatment is the most commonly preferred treatment method in these diseases as the inhalers provide ease of use; the medicaments have rapider onset of time resulting from local administration and they have fewer side effects.
  • Various inhalers have been designed in order to provide effective and sufficient delivery of the medicaments used in the treatment of respiratory diseases, particularly in asthma and chronic obstructive pulmonary disease. These inhalers vary according to their operating mechanisms, some properties they hold and the physical form of the medicament to be delivered.
  • the medicament is carried in reservoirs, capsules or blisters packages. It is highly significant to deliver sufficient amounts of the medicament to the patient since the amount of dry powder medicament that is to be delivered to the patient for each inhalation is very low.
  • one dose of dry powder medicament is administered to the patient generally via a valve or a mechanical component in the device during each inhalation.
  • the inhalers comprising capsules there is a metered dose of dry powder medicament in the capsule which is to be placed in the inhaler before each inhalation.
  • one capsule is pierced or opened by another method and the dry powder medicament contained in the capsule becomes ready for inhalation.
  • the inhalers comprising blister packs at least one blister pocket is opened when the blister package is indexed and the dry powder medicament metered with high preciseness becomes ready for inhalation.
  • the inhalers in which the dry powder medicament is carried in blister packs or capsules can be multiple-dose or single-dose inhalers.
  • the term “multiple-dose inhaler” refers to inhalers comprising more than one medicament dose.
  • the inhalers enabling the inhalation of dry powder medicament from capsules are commonly used.
  • one capsule is placed in the capsule chamber of the device before each inhalation in these devices; the capsule in the capsule chamber of the device is pierced, cut or opened by similar methods when the device is actuated, and the dry powder medicament contained in the capsule becomes ready for inhalation.
  • the amount of the active agent in one dose of dry powder medicament is quite low.
  • absorption of a sufficient amount of the active agent in the patient's lung is essential in order to realize an effective inhalation.
  • Absorption of less than the required amount of the active agent in the patient's lung remains insufficient for an effective treatment.
  • the flow rate required to ensure a pressure decrease of 4 kPa during inhalation that the patient has to apply is high when the resistance of the inhaler is low.
  • ⁇ represents the pressure decrease required to be ensured in the inhaler for an effective inhalation and it values 4kPa.
  • Rd and Q in the equation represent the resistance of the inhaler and the flow rate that the patient has to apply during the inhalation respectively. The fact that the flow rate that the patient has to apply is high requires the patient to spend more effort during the inhalation to ensure the pressure decrease of 4 kPa in the inhaler.
  • the diameter of the air intake duct which ensures to deliver the dry powder medicament in the capsule to the patient via the inhaler during inhalation affects the resistance of the inhaler to a substantial extent.
  • the present invention relates to an inhaler which comprises capsule and enables effective inhalation of dry powder medicament even at low flow rates during inhalation.
  • the inhaler of the present invention which comprises capsule containing the medicament in dry powder form described above characterized in that the diameter of the air intake duct through which the air flow entraining the dry powder from the capsule to the mouthpiece passes is preferably in the range of 3.5 mm to 6.5 mm, more preferably in the range of 4.0 mm to 5.5 mm.
  • the flow rate that must be applied by the patient is in the range of 20 L/min to 50 L/min when the diameter of the air intake duct is in the range of 3 mm to 7 mm; and flow rate values varying in this range can easily be applied by almost all patients at different ages and strength.
  • an inhalation refers to an inhalation in which a sufficient amount of active agent required for an effective treatment is delivered to the patient's lungs.
  • resistance of the inhaler refers to resistance of the inhaler against air flow.
  • flow rate refers to volume of air flow that the patient must apply per minute during the inhalation of the medicament in dry powder form in the inhaler.
  • the present invention provides an inhaler which enables to deliver a sufficient amount of the dry powder medicament used in the treatment of respiratory diseases to the patient's lungs.
  • the air intake duct is preferably made of a material having a sufficiently high friction coefficient and/or the inner surface of the air intake duct which is in contact with the air flow entraining dry powder medicament is coated with a material having a sufficiently high friction coefficient.
  • the inner surface of the air intake duct is smooth so as to prevent dry powder particles to be confined to the air intake duct.
  • the material used to produce the air intake duct or the coating material used to coat the inner surface of the air intake duct can be any material which has a sufficiently high friction coefficient though it is preferably selected from, but not limited to, a group comprising aluminum, steel, plastic, iron, copper, nickel, brass, zinc and/or a combination thereof.
  • Friction coefficient of the materials used in production of said air intake duct and/or coating of inner surface of said air intake duct is in the range of 0.01 to 5, preferably in the range of 0.1 to 3, more preferably in the range of 0.1 to 2.5.
  • Thickness of the coating on the inner surface of the air intake duct of the inhaler comprising capsule is preferably in the range of 1-40 ⁇ , more preferably in the range of 5- 30 ⁇ .
  • the air intake duct inserted into the mouthpiece can be cylindrical or tapered. If the duct is tapered, the end of the duct through which the air flow entraining the dry powder medicament enters is preferably wide while the end of the duct which communicates with the patient's mouth is narrow. Thus, the air flow entraining medicament particles which exits the capsule, passes through the sieve and arrives in the air intake duct in the mouthpiece enters the wide end of the duct, pass through the duct that narrows through the other end and reaches the patient.
  • holes on the walls of the air intake duct in order to create turbulence in the air flow which passes through the air intake duct and entrains medicament in dry powder form.
  • Number of these holes is at least two though they may have identical or different diameters.
  • the holes are situated symmetrically or asymmetrically on the walls of the air intake duct.
  • the inhaler of the present invention comprises preferably a pierceable capsule containing medicament in dry powder form.
  • the inhaler of the present invention is composed of various components in order to ensure inhalation of the dry powder medicament contained in the capsule.
  • the mouthpiece cover covers the mouthpiece and provides to keep it clean.
  • the mouthpiece which is exposed when the mouthpiece cover is opened is joined with the middle casing and they synchronize.
  • the capsule containing the medicament in dry powder form and the mechanism of the device are situated in the bottom casing.
  • the middle casing On the sides of the middle casing, there are holes used as pin holders. The pins placed in these pin holders enable the mouthpiece cover, mouthpiece, middle casing with the mouthpiece, capsule chamber and the bottom casing to easily move around the pin they are attached to.
  • Mechanism of the device is situated in the bottom casing of the inhaler.
  • the mechanism is composed of components which contribute to the inhaler of the present invention to work properly and the medicament in dry powder form contained in the capsule to be prepared for inhalation.
  • the piercing needles which pierce the capsule; the needle carrier; the springs which enable the needle carrier to move towards and away from the capsule chamber and to be positioned correctly according to the needles are among components constituting the mechanism of the device.
  • the connecting rod in the capsule chamber is inserted through the spring and the hole in the center of the needle carrier between the capsule chamber and the needle carrier and provides said spring to be positioned on it.
  • said spring is situated between the capsule chamber and the needle carrier.
  • the other spring in the mechanism of the device is on the other side of the needle carrier, between the needle carrier and the inner surface of the bottom casing.
  • the needle carrier is situated between the two springs.
  • the capsule chamber At the outlet of the capsule chamber, there placed a sieve and a sieve holder above the sieve providing to keep it fixed.
  • the air intake duct inserted into the mouthpiece is also fixed into this sieve. Therefore, the air exiting the capsule chamber passes through the sieve, the sieve holder and the air intake duct before being delivered to the patient as the air intake duct is on the same axis with the sieve and the sieve holder.
  • the capsule chamber cover covering the capsule chamber provides to protect the capsule chamber and the mechanism of the device from external factors.
  • the mouthpiece Prior to inhalation, the mouthpiece which synchronizes preferably with the middle casing has to be rotated outwards around the pin it is joined with in order to place the capsule containing the medicament in dry powder form in the capsule chamber. This movement of the mouthpiece is maintained until the capsule chamber gets to an available position for placing a capsule. For the capsule to be pierced after being placed in the capsule chamber, the mouthpiece has to be moved towards the capsule chamber. During the move of the mouthpiece towards the capsule chamber, while the pawls at the ends of the cogs reaching down under the mouthpiece are advancing on the rails in both sides of the needle carrier, the needle carrier compresses the spring and the piercing needles are moved towards the capsule.
  • the air flow entering the device upon inhalation of the patient flows through the holes of the capsule in the capsule chamber and entrains the dry powder medicament in the capsule out. Subsequently, the air flow entraining the dry powder medicament ensures the delivery of the medicament in dry powder form to the patient passing through the sieve, sieve holder and the air intake duct.
  • the mouthpiece is moved outwards after the dry powder medicament in the pierced capsule is inhaled by the patient and removed from the capsule chamber.
  • the capsule chamber is exposed when the mouthpiece is moved outwards around the pin it is attached to.
  • the discharged capsule is ejected from the capsule chamber after the inhalation and the capsule chamber is cleaned properly if required.
  • the mouthpiece and the mouthpiece cover are kept close until the next inhalation.
  • the inhalation device of the present invention comprising capsule can be made of the same or different materials.
  • each component of the inhaler can be made of a suitable material though it is preferably selected from a group comprising styrene- acrylonitrile, polyoxymethylene, acrylic polymethyl metacrylate, cellulose acetate, polyetheretherketone, polyvinyl chloride, polyethylene, polypropylene, acrylonitrile butadiene styrene, silicon, polycarbonate, polyamide, polystyrene, polyurethane or fluoropolymer types.
  • each component of the device can be in any suitable color.
  • the capsule used in the inhaler comprising a capsule pertaining to the present invention can be made of any suitable substance though it is preferably made of a material selected from a group comprising gelatin, chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers.
  • the capsule of the present invention is composed of intertwining top and bottom compartments. The top and the bottom compartments of said capsule can be made of identical or different materials.
  • the capsule material can be selected from, but not limited to, a group comprising hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose.
  • the capsule material can be selected from, but not limited to, a group comprising polyethylene, polyetheleneteraphtalate, polycarbonate or polypropylene.
  • capsule material used in the present invention is gelatine
  • additional agents such as polyethylene glycol, sorbitol, glycerol, propylene glycol, polyethylene oxide - polypropylene oxide block copolymers and/or other polyalcohols and polyethers at different molecular weights can be added into it.
  • the volume of the capsule containing the dry powder medicament in the inhaler of the present invention is in the range of 0.10 ml to 0.70 ml, preferably in the range of 0.10 ml to 0.52 ml and it is filled up to 0,01-30 %, preferably 0,01-25 % of said volume.
  • the capsule pack containing the dry powder medicament and used in the inhaler of the present invention can be in any suitable shape and color on condition that it holds the specifications mentioned above.
  • Figure 1 is a front view of the inhaler of the present invention.
  • Figure 2 is an exploded view of the inhaler of the present invention.
  • Figure 3 is a view of the communication of the main components of the device of the present invention.
  • Figures 4a and 4b are views of the capsule chamber together with the needle carrier of the inhaler of the present invention.
  • Figure 5 is a view of route that the mouthpiece of the inhaler of the present invention follows during its move towards the capsule chamber.
  • Figure 6 is a view of the capsule chamber together with the mouthpiece when the mouthpiece of the inhaler of the present invention is entirely closed.
  • Figure 7 is a view of the capsule chamber together with the mouthpiece and the middle casing when the mouthpiece is entirely closed.
  • Figures 8 a- 8b are plan and bottom views of the mouthpiece of the inhaler of ht epresent invention respectively.
  • the inhaler of the present invention illustrated in Figure 1 is in pre-use position. In pre-use position, only the mouthpiece cover (1) hiding the mouthpiece; the bottom casing (2) where the mechanism of the device is situated; and the middle casing (3) are visible.
  • the mouthpiece cover (1) covers the movable mouthpiece (3') component which is connected with the bottom casing (2) of the inhaler in pre-use position. Therefore, the mouthpiece cover (1) enables to keep the mouthpiece (3') clean in pre-use position and carry it everywhere comfortably.
  • the mechanism of the inhaler of the present invention and the capsule chamber (13) are situated in the bottom casing (2) of the device.
  • the mechanism of the inhaler is composed of constituents which contribute to ensure proper operation of the inhaler of the present invention and prepare the medicament in dry powder form contained in the capsule of the inhaler for inhalation.
  • the piercing needles (9a, 9b) that pierce the capsule, the needle carrier (8), the springs (10a, 10b) which enable the needle carrier to easily move towards and away from the capsule chamber and keep the needle carrier at the accurate position according to the positions of the needles are among the constituents composing the mechanism of the inhaler.
  • the mouthpiece (3') and the middle casing (3) are joined and they synchronize.
  • the capsule chamber cover (13a) which covers the capsule chamber (13) ensures protection of the capsule chamber (13) and the mechanism of the inhaler from external factors.
  • FIG 3 the mouthpiece cover (1), the bottom casing (2), the middle casing (3) and the mouthpiece (3') which are the main components of the inhaler and the positions of each around the pins (12a, 12b) they are attached to are illustrated.
  • the upper pin (12a) and the lower pin (12b) are kept in a precise position by the pin holders (3a, 3b, 3c, 3d) on the middle casing (3).
  • the upper pin (12a) is hold by the pin holders (3a, 3c) on the upper part of the middle casing; the lower pin (12b) is hold by the pin holders (3b, 3d) on the lower part of the middle casing.
  • the mouthpiece cover (1) of the inhaler of the present invention is joined with the upper pin (12a); the bottom casing (2), the middle casing (3), the mouthpiece (3') and the capsule chamber (13) are joined with the lower pin (12b), and these components can be easily rotated around the pins they are joined.
  • the mouthpiece cover (1) is joined with the upper pin (12a) via the mouthpiece pin hole (la); the bottom casing (2) and the capsule chamber (13) are joined with the lower pin (12b) via the bottom casing pin hole (2a) and the capsule chamber pin hole (13b) respectively.
  • the needle carrier (8) is illustrated with the capsule chamber (13).
  • the needles (9a, 9b) held by the needle carrier (8) go through these holes (15a, 15b) on the capsule chamber (13) and pierce the capsule.
  • the connection rod (11) in the capsule chamber (13) goes into the hole (8a) in the center of the needle carrier (8) with the spring (10a) between the capsule chamber (13) and the needle carrier (8).
  • the other spring (10b) in the mechanism of the inhaler is on the other side of the needle carrier (8), between the needle carrier (8) and the inner surface of the bottom casing (2).
  • the needle carrier (8) is situated between the two springs (10a, 10b).
  • This spring (10b) on the other side of the needle carrier (8) enables accurate and exact positioning of the needle carrier (8) when the mouthpiece (3') is completely closed.
  • the needle carrier (8) compresses the spring (10a) and the piercing needles (9a, 9b) move towards the capsule.
  • the mouthpiece of the inhaler of the present invention which is joined with the middle casing is shown from different perspectives in figure 8a and figure 8b.
  • the air intake duct (5) which is inserted into the mouthpiece (3') ensures delivery of the air flow entraining the medicament in dry powder form to the patient.
  • the air intake duct (5) which is inserted into the mouthpiece (3') also fits into this sieve holder (7).
  • the air intake duct (5) is on the same axis with the sieve (6) and the sieve holder (7), the air exiting the capsule chamber (13) passes through the sieve (6), the sieve holder (7) and the air intake duct (5) and reaches the patient.
  • the mouthpiece (3') is moved outwards and removed from the capsule chamber (13).
  • the capsule chamber (13) is exposed when the mouthpiece (3') synchronizing with the middle casing (3) is moved outwards around the pin it is joined.
  • the capsule discharged after inhalation is ejected from the capsule chamber (13) and the capsule chamber (13) is cleaned properly if required.
  • the mouthpiece (3') and the mouthpiece cover (1) are kept close (figure 1) until the following inhalation.
  • the capsule containing the dry powder medicament in the inhaler of the present invention is produced according to the prior art.
  • the particle size of the active agents contained in the capsule is less than 20 ⁇ , preferably less than 10 ⁇ .
  • the inhaler of the present invention has been designed so as to deliver the dry powder medicament used in monotherapy or combined therapy.
  • monotherapy refers to inhalation treatments in which dry powder medicaments comprising a single active agent are used whereas the term “combined therapy” refers to inhalation treatments in which dry powder medicaments comprising more than one active agents are used.
  • the dry powder medicament delivered via the device of the present invention comprises at least one excipient in addition to the active agent or agents.
  • excipients are generally chosen from a group comprising monosaccharides (glucose, arabinose, etc.), disaccharides (lactose, saccharose, maltose, etc.), oligo- and polysaccharides (dextran, etc.), polyalcohols (sorbite, mannite, xylite), salts (sodium chloride, calcium carbonate, etc.) or combinations thereof.
  • the medicament in dry powder form comprises lactose as the excipient.
  • the medicament in dry powder form comprises fine or coarse excipient particles preferably having various particle size ranges in order to deliver the required amount to the lungs.
  • the active agent or the active agents comprised in the dry powder medicament which is stored in capsules used in the device of the present invention can be selected from a group comprising cromolyns, anti-infectives, antihistamines, steroids, anti-inflammatories, bronchodilators, leukotirene inhibitors, PDE IV inhibitors, antitussives, diuretics, anticholinergics, hormones, xanthines and pharmaceutically acceptable derivatives thereof.
  • the active agent comprised in the medicament in dry powder form delivered via the inhaler of the present invention is preferably selected from a group comprising tiotropium, oxitropium, flutropium, ipratropium, glicopironium, flunisolid, beclomethasone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, dexamethasone, montelukast, methylcyclopropane acetic acid, sodium cromoglicat, nedocromil sodium, Npropylene, teophylline, roflumilast, ariflo (cilomilast), salmeterol, salbutamol, formoterol, terbutaline, carmoterol, indacaterol, cetirizine, levocetirizine, efletirizine, fexofenadine and their racemates, free base, enantiomers or diastereomers and their pharmaceutical
  • the device of the present invention is used in the administration of the medicament in dry powder form which is utilized in the treatment of respiratory diseases, particularly in asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
  • the respiratory diseases include, but not restricted to, allergic or non-allergic asthma at any phases, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), exacerbation of airways hyperactivity, bronchiectasis, chronic obstructive pulmonary including emphysema and chronic bronchitis, airways or lung diseases (COPD, COAD or COLD), pneumoconiosis, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.
  • the device pertaining to the invention can be used in prophylactic or symptomatic treatment.
  • the medicament in dry powder form which is preferably used in the symptomatic treatment of
  • tables 1-5 illustrate flow rate (Q) values required to be applied by the patient during inhalation at different diameter values (d) of air intake duct in order to ensure standard pressure decrease ( ⁇ ) of 4 kPa in the inhaler of the present invention after the capsule is pierced.
  • d diameter values
  • ⁇ standard pressure decrease
  • 10 measurements were conducted. Analysis results under given condition are as follows. As can be seen in the tables, in the case that the diameter of the duct fixed into the mouthpiece is in the range of 3 mm to 6 mm, the flow rate required to be applied by the patient in order to provide standard pressure decrease of 4 kPa is rather low.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un inhalateur qui est approprié pour l'administration de médicaments sous forme de poudre sèche à partir de capsules. L'inhalateur comprend un couvercle d'embout buccal (1) recouvrant l'embout buccal, un boîtier inférieur (2) dans lequel est placé le mécanisme du dispositif, un embout buccal mobile (3') communiquant avec le boîtier inférieur, un boîtier intermédiaire (3) situé entre le boîtier inférieur et l'embout buccal, un compartiment de capsule (13) recevant la capsule, et un conduit d'entrée d'air (5) qui est inséré dans l'embout buccal. L'inhalateur est caractérisé en ce que le diamètre du conduit d'entrée d'air (5) à travers lequel circule le flux d'air entraînant le médicament en poudre sèche de la capsule à l'embout buccal, se situe dans un intervalle de 3-7 mm, ce qui entraîne une augmentation de la résistance à l'écoulement dans l'inhalateur. Il en résulte que le débit d'air devant être appliqué par le patient pour créer la dépression standard de 4 kPa est réduit. Cet inhalateur permet par conséquent une inhalation efficace d'un médicament sous forme de poudre sèche même à des faibles débits d'air lors de l'inhalation.
EP11787953.6A 2010-10-07 2011-10-06 Inhalateur comprenant une capsule Withdrawn EP2624897A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/08226A TR201008226A2 (tr) 2010-10-07 2010-10-07 Kapsül içeren bir inhalasyon cihazı.
PCT/TR2011/000225 WO2012047181A1 (fr) 2010-10-07 2011-10-06 Inhalateur comprenant une capsule

Publications (1)

Publication Number Publication Date
EP2624897A1 true EP2624897A1 (fr) 2013-08-14

Family

ID=45034154

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11787953.6A Withdrawn EP2624897A1 (fr) 2010-10-07 2011-10-06 Inhalateur comprenant une capsule

Country Status (3)

Country Link
EP (1) EP2624897A1 (fr)
TR (2) TR201008226A2 (fr)
WO (1) WO2012047181A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248247B2 (en) 2012-07-26 2016-02-02 Nathaniel Gerald Portney Capsular medication delivery and inhalation device
WO2014204417A1 (fr) * 2013-06-19 2014-12-24 Mahmut Bilgic Dispositif d'inhalation comprenant une plaque flexible
CA173518S (en) 2016-02-08 2017-09-01 Nicoventures Holdings Ltd Cartridge for an electronic cigarette
GB201605105D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Vapour provision apparatus
GB201605101D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Electronic vapour provision system
GB201605102D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Mechanical connector for electronic vapour provision system
GB201605100D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Vapour provision system
EP3487776A1 (fr) 2016-07-22 2019-05-29 Nicoventures Holdings Limited Boîtier pour dispositif de fourniture de vapeur
DE202017102334U1 (de) 2016-08-25 2017-11-29 Alfred Von Schuckmann Vorrichtung zum Inhalieren pulverförmiger Substanzen
CN115429986B (zh) * 2022-08-25 2023-07-18 苏州易合医药有限公司 一种用于软球颗粒药物递送的吸入装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80123C2 (en) * 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
US20030235538A1 (en) * 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
DE10300982A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
JP5504156B2 (ja) * 2007-06-15 2014-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器
EP2082762A1 (fr) * 2008-01-24 2009-07-29 Boehringer Ingelheim International Gmbh Inhalateur
DE102008014025A1 (de) * 2008-03-13 2009-09-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator und Sieb für einen Inhalator
TR200803522A1 (tr) * 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Kolay kullanımlı inhalasyon cihazı.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2012047181A1 *

Also Published As

Publication number Publication date
TR201109439A2 (tr) 2012-04-24
TR201008226A2 (tr) 2012-04-24
WO2012047181A1 (fr) 2012-04-12

Similar Documents

Publication Publication Date Title
EP2624898B1 (fr) Dispositif d'inhalation de poudre sèche en doses uniques
EP2624897A1 (fr) Inhalateur comprenant une capsule
US10842952B2 (en) Dry powder inhaler
TWI592180B (zh) 乾燥粉末吸入器
EP2782488B1 (fr) Dispositif d'inhalation
RU2648849C2 (ru) Устройство для доставки лекарственного средства для лечения пациентов с заболеваниями органов дыхания
EP2575786B1 (fr) Procédé pour formulations pulvérulentes sèches
WO2014204417A1 (fr) Dispositif d'inhalation comprenant une plaque flexible
JP2013523375A (ja) 乾燥粉末吸入器のマウスピースボタン
EP2558148B1 (fr) Bouton d'embout buccal pour inhalateur à poudre sèche
EP2558149A1 (fr) Bouton d'embout buccal pour inhalateur à poudre sèche
WO2011129790A1 (fr) Inhalateur créant une turbulence
WO2011149436A1 (fr) Inhalateur de poudre sèche amélioré
JP5873477B2 (ja) 乾燥粉末形態の薬剤の送達に使用する吸入器
WO2011149435A1 (fr) Inhalateur de poudre
CN111315432A (zh) 吸入器和用于吸入器的网格

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130507

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200805